Carrege Therapeutics

Carrege Therapeutics is a pre-clinical stage biotechnology company developing a proprietary platform for the precision delivery of genetic medicines. Spun out of the University of California, Berkeley, the company leverages its CARREGE (Cell-surface Anchored REceptor-mediated Gene Entry) technology to enable tissue-specific targeting of RNA and gene therapies. This platform utilizes engineered molecular bridges to facilitate the entry of therapeutic payloads into specific cell types, aiming to overcome the limitations of current systemic delivery methods. Carrege's primary focus is on addressing unmet needs in central nervous system and neuromuscular disorders through enhanced delivery efficiency and reduced off-target toxicity. The company's approach integrates advanced viral vector engineering with innovative biomaterials to create a versatile delivery toolkit. It is currently advancing several discovery-stage programs aimed at high-value therapeutic targets.